Alar PharmaceuticalsROCO:6785 52 PB Ratio is 3.25 as of Jul. 13, 2026, which is 53% below its 10-year median of 6.91. GuruFocus rates ROCO:6785 with a GF Score™ of 52/100 and a GF Value™ of NT$90.64 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 924 Drug Manufacturers companies, Alar Pharmaceuticals ranks worse than 71% on this metric.
Alar Pharmaceuticals Inc stock PB Ratio (=3.25) is close to 5-year low of 3.15.
The historical rank and industry rank for Alar Pharmaceuticals's PB Ratio or its related term are showing as below:
ROCO:6785'
s PB Ratio Range Over the Past 10 Years
Min: 3.15 Med: 6.91 Max: 27.64
Current: 3.25
During the past 9 years, Alar Pharmaceuticals's highest PB Ratio was 27.64. The lowest was 3.15. And the median was 6.91.
ROCO:6785's PB Ratio is ranked worse than 71% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs ROCO:6785: 3.25
During the past 12 months, Alar Pharmaceuticals's average Book Value Per Share Growth Rate was -3.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 58.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 36.40% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Alar Pharmaceuticals was 209.30% per year. The lowest was 14.40% per year. And the median was 48.80% per year.
Back to Basics: PB Ratio
Alar Pharmaceuticals (ROCO:6785) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alar Pharmaceuticals PB Ratio Related Terms
Alar Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alar Pharmaceuticals (ROCO:6785) has a PB Ratio of 3.25 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alar Pharmaceuticals and its competitors. This is 53% below median its historical median of 6.91. Over the past decade, Alar Pharmaceuticals' PB Ratio has ranged from 3.15 to 27.64. According to the industry distribution chart, Alar Pharmaceuticals ranks #656 out of 924 companies in the Drug Manufacturers industry, placing it in the top 71%.
Is Alar Pharmaceuticals' PB Ratio too high?
Alar Pharmaceuticals' current PB Ratio of 3.25 is 53% below median its 10-year median of 6.91. Over the past 10 years, this metric has ranged from a low of 3.15 to a high of 27.64. The Drug Manufacturers industry median PB Ratio is 1.91. Alar Pharmaceuticals' value of 3.25 is 70.2% above this industry median. Based on the distribution chart, Alar Pharmaceuticals ranks #656 out of 924 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #656 out of 924 companies for PB Ratio. This places Alar Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.91. Alar Pharmaceuticals' value of 3.25 is 70.2% above this benchmark. Historically, Alar Pharmaceuticals' own PB Ratio has ranged from 3.15 to 27.64 over the past decade. While the company's 10-year median is 6.91 vs. the industry median of 1.91, Alar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alar Pharmaceuticals's current PB Ratio of 3.25 is 70.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current PB Ratio is 3.25, which is 53% below median its own 10-year median of 6.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current PB Ratio is 3.25, which is 53% below median its 10-year median of 6.91 and 70.2% above the Drug Manufacturers industry median of 1.91. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current PB Ratio is 3.25 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
PB Ratio: 3.25 (53% below median its 10-year median of 6.91)
GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
Industry Position: 70.2% above the Drug Manufacturers median (#656 of 924)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score
Get the complete analysis for ROCO:6785
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
